Please provide your email address to receive an email when new articles are posted on . Rituximab is associated with higher protection against long-term cardiovascular and metabolic diseases, but ...

Although relapse rates were similar across all treatment categories, patients with GPA treated with rituximab monotherapy had a lower relapse risk relative to those on rituximab + cyclophosphamide ...

Zenyaku Kogyo obtains Japanese approval for anti-CD20 monoclonal antibody, Rituxan to treat autoimmune haemolytic anaemia: Tokyo Friday, February 20, 2026, 13:00 Hrs [IST] Zenyaku ...

In this open-label trial, a higher proportion of asymptomatic follicular lymphoma patients assigned to rituximab required no further treatment at nearly 15 years compared with those assigned to ...

Please provide your email address to receive an email when new articles are posted on . Patients with pemphigus treated with rituximab had a longer disease-free survival than those treated with ...

Learn the difference between induction and maintenance phases in ANCA-associated vasculitis (AAV) treatment, including what to expect from medications like rituximab (Rituxan).

A retrospective analysis suggested that administering rituximab to patients with rheumatoid arthritis complicated by lymphoma, systemic vasculitis, or extra-articular lesions was associated with ...

No patient in the 6-month rituximab group relapsed during the 24-month follow-up, and 1 patient in the 12-month group had a minor relapse. Tailored, risk-stratified rituximab regimens including yearly ...

Late-onset neutropenia (LON) is emerging as a common adverse effect to rituximab therapy owing to widespread use of this drug in the treatment of B-cell lymphomas and autoimmune diseases. However, the ...

LONDON (MarketWatch) -- Favrille Inc. said that its Phase II clinical trial of FavId following Rituxan treatment in patients with follicular B-cell non-Hodgkin's lymphoma at the American Society of ...

Prognostic Significance of Partial Tandem Duplications of the MLL Gene in Adult Patients 16 to 60 Years Old With Acute Myeloid Leukemia and Normal Cytogenetics: A Study of the Acute Myeloid Leukemia ...